[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc (ORKA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,834,548
  • Shares Outstanding, K 50,197
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,430 K
  • EBIT $ -122 M
  • EBITDA $ -127 M
  • 60-Month Beta -0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.13

Options Overview Details

View History
  • Implied Volatility 93.92% (+1.84%)
  • Historical Volatility 67.62%
  • IV Percentile 7%
  • IV Rank 14.68%
  • IV High 206.40% on 09/10/25
  • IV Low 74.57% on 03/19/26
  • Expected Move (DTE 17) 9.44 (12.75%)
  • Put/Call Vol Ratio 1.64
  • Today's Volume 412
  • Volume Avg (30-Day) 360
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 6,333
  • Open Int (30-Day) 2,659
  • Expected Range 64.56 to 83.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.52
  • Number of Estimates 5
  • High Estimate $-0.49
  • Low Estimate $-0.63
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.50 +70.09%
on 03/30/26
91.00 -18.69%
on 04/27/26
+29.51 (+66.34%)
since 03/27/26
3-Month
31.00 +138.68%
on 02/11/26
91.00 -18.69%
on 04/27/26
+38.83 (+110.44%)
since 01/28/26
52-Week
8.91 +730.42%
on 05/15/25
91.00 -18.69%
on 04/27/26
+63.71 (+619.75%)
since 04/28/25

Most Recent Stories

More News
Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.01%. June E-mini...

ALK : 39.79 (-1.61%)
UAL : 90.41 (-1.62%)
AMAT : 381.11 (-5.87%)
SNDK : 1,002.35 (-6.34%)
VZ : 47.24 (+0.30%)
ADI : 383.26 (-2.38%)
TXN : 265.00 (-1.67%)
$IUXX : 27,029.01 (-1.01%)
ELV : 362.74 (+1.86%)
UNH : 366.77 (+3.41%)
ASML : 1,384.56 (-3.34%)
DPZ : 340.46 (+1.54%)
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics...

ORKA : 73.99 (-3.14%)
Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. June E-mini S&P futures...

ALK : 39.79 (-1.61%)
UAL : 90.41 (-1.62%)
AMAT : 381.11 (-5.87%)
SNDK : 1,002.35 (-6.34%)
VZ : 47.24 (+0.30%)
ADI : 383.26 (-2.38%)
TXN : 265.00 (-1.67%)
$IUXX : 27,029.01 (-1.01%)
DPZ : 340.46 (+1.54%)
ZNM26 : 110-275s (-0.15%)
ESM26 : 7,171.00s (-0.49%)
NCLH : 17.79 (-2.20%)
Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX ) (SPY ) today is unchanged, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. June E-mini S&P futures (ESM26...

AAPL : 270.71 (+1.16%)
CRWD : 454.99 (+0.08%)
VZ : 47.24 (+0.30%)
$SPX : 7,138.80 (-0.49%)
MU : 504.29 (-3.86%)
MANE : 103.10 (+3.00%)
$IUXX : 27,029.01 (-1.01%)
NQM26 : 27,168.75s (-0.99%)
DPZ : 340.46 (+1.54%)
QQQ : 657.55 (-1.01%)
CLM26 : 99.93s (+3.69%)
ZNM26 : 110-275s (-0.15%)
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing,...

ORKA : 73.99 (-3.14%)
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 73.99 (-3.14%)
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run?

Oruka Therapeutics (ORKA) has strong technical momentum and is trading at a new 5-year high. Shares are up nearly 840% over the past year. ORKA maintains a 100% “Buy” technical opinion from Barchart....

ORKA : 73.99 (-3.14%)
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...

ORKA : 73.99 (-3.14%)
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 73.99 (-3.14%)
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies...

ORKA : 73.99 (-3.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo.

See More

Key Turning Points

3rd Resistance Point 102.95
2nd Resistance Point 96.98
1st Resistance Point 86.68
Last Price 73.99
1st Support Level 70.41
2nd Support Level 64.44
3rd Support Level 54.14

See More

52-Week High 91.00
Last Price 73.99
Fibonacci 61.8% 59.64
Fibonacci 50% 49.96
Fibonacci 38.2% 40.27
52-Week Low 8.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.